oral TLR7 agonist RG7854 and HBV core protein allosteric modulator RG7907. Dicerna is retaining an option to co-fund pivotal development of the product globally, which would entitle the company to ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
It revealed that the HBV X gene, which produces HBx protein, is particularly sensitive to the formation ... from MSK's atomic force microscopy imaging at its Molecular Cytology Core to the Genomics ...
Introduction: The aim of this study was to investigate the association between hepatitis B core antibody (HBcAb ... Absence of five indicators of HBV or inadequate medical records. This study was ...
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure ...
Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...
“His interest in epigenetic regulation in pathogens immediately made me consider HBV an ideal model system for him to explore,” Dr. David says. At the heart of the mystery that intrigued the ...
Conclusion: Both core promoter and YMDD motif mutation(s ... Analysis of lamivudine-resistant strains of HBV DNA has invariably shown nucleotide substitutions that induce amino acid changes ...
Inovio’s performance in Q4 2024 shows a strategic shift towards reducing costs and focusing on core projects. The company’s operating expenses were trimmed by 22%, down from $144.8 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback